Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.amgen.com
Amgen Inc. News Releases
Get the latest updates from Amgen Inc. News Releases directly as they happen.
Follow now 192 followers
Latest posts
Last updated 4 days ago
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
4 days ago
Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival...
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
3 months ago
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile...
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
3 months ago
THOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present...
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
3 months ago
VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular...
AMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS
about 2 months ago
THOUSAND OAKS, Calif., July 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced...
POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE
about 2 months ago
Repatha is the Only PCSK9 Inhibitor Proven to Significantly Reduce Risk of...
AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
about 1 month ago
THOUSAND OAKS, Calif., July 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced...
AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
about 1 month ago
THOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today...
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
17 days ago
Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo...
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
13 days ago
Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the...
AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
10 days ago
THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will...
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
6 months ago
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of...